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100,000 persons. RESULTS: From 2007–2009, incidence of reportable invasive SP
pneumonia decreased linearly from 11.7/100,000 to 7.1/100,000. Incidence in-
creased with age; adults aged 65 years consistently had the highest incidence
(2007: 39.4/100,000; 2009: 24.4/100,000), with the lowest rates observed in adults
aged 20–49 years (2009: 3.35/100,000). In-hospital mortality rates were 6%
throughout the study, with the highest rates in adults aged 65 years (2009: 8.8%).
SP was the most common pathogen reported (1,358/1,544 [88%] isolates). The pro-
portion of 7-valent pneumococcal conjugate vaccine (PCV7) serotypes decreased
from 46.7% to 20.1%, while the number and proportion of non-PCV7, 13-valent
pneumococcal conjugate vaccine (PCV13) serotype disease increased, led by 19A
(n7 [1.3%] to n23 [6.9%]). The most frequently identified serotypes in 2009 were
7F (16.8%), 1 (11.4%), 22F (11.4%), 4 (8.4%), 19A (6.9%), and 3 (6.6%). In children aged
0–4 years, 8, 1, and 0 cases of PCV7 invasive SP pneumonia occurred in 2007, 2008,
and 2009, respectively. PCV13 serotypes caused 64.9% of invasive SP pneumonia in
2009, the majority in adults aged60 years. CONCLUSIONS: Although incidence of
reportable invasive pneumonia decreased in Norway from 2007–2009, after the
pediatric PCV7 National Immunization Program was fully underway, substantial
disease burden remains, particularly in older adults. Almost 65% of invasive SP
pneumonia cases were caused by pneumococcal conjugate vaccine serotypes.
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OBJECTIVES: Pneumonia is associated with substantial burdens on patient mor-
bidity and mortality, and health care resources across all age groups. A retrospec-
tive database study was conducted to assess the burden of disease associated with
hospitalized all-cause pneumonia in terms of incidence, in-hospital mortality,
length-of-stay (LOS), and hospitalization cost in the Italian regions of Lombardia
and Puglia from 2007–2009. METHODS: Data were obtained from two Local Health
Units (LHUs) in Lombardia and Puglia. All patients with an ICD-9 code diagnosis of
pneumonia (480, 481, 482, 483, 484, 485, 486, and 487) from January 1, 2007–Decem-
ber 31, 2009 were included. Incidence rates were calculated based on the number of
people per LHU and reported annually as cases per 1,000 persons. RESULTS: In
total, 10,195 patients hospitalized for pneumonia were included in this study. In-
cidence of hospitalizations increased slightly from 2007–2009 (2007: 1.91/1,000;
2008: 1.86/1,000; 2009: 2.00/1,000). In children aged 0–4 years, incidence decreased
from 5.57/1,000 in 2007 to 3.85/1,000 in 2009, while incidence in adults aged 65
years increased from 5.36/1,000 to 6.59/1,000. In-hospital deaths occurred in 196
patients (5.9%) in 2007 and 202 (5.2%) patients in 2009, with the highest mortality
observed in adults aged65 years (176 patients [9.5%] and 191 [8.1%], respectively).
No in-hospital deaths occurred in children aged 0–4 years. Mean LOS was similar
(2007: 10.5 days; 2008: 10.8 days; 2009: 11.0 days), and increased with age. Mean cost
per patient was €2,966 in 2007, €3,073 in 2008, and €3,218 in 2009. CONCLUSIONS:
Reductions in hospitalized pneumonia were observed in children aged 0–4 years;
however, overall incidence of hospitalized pneumonia slightly increased during
the study period driven by increased hospitalizations in older adults. Adults aged
65 years had the highest disease burden in terms of incidence, in-hospital mor-
tality, mean hospital LOS, and costs.
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OBJECTIVES: International randomized, multicenter, double-blinded studies dem-
onstrated that boceprevir, added to peginterferon alpha-2b and ribavirin signifi-
cantly increased sustained virologic response rates over peginterferon/ribavirin
alone in treatment-naïve (SPRINT-2) and treatment-experienced (RESPOND-2)
adult patients with chronic hepatitis C virus genotype 1 infection. Our objective
was to project the reduction in the lifetime incidence of liver-related morbidity and
mortality associated with treatment with boceprevir/peginterferon/ribavirin vs.
treatment with peginterferon/ribavirin vs. no treatment. METHODS: A multi-co-
hort Markov model was developed using German life tables and baseline patient
demographics from the trials— mean age, gender, and fibrosis stage distribution.
The first part of the model simulated three strategies—treatment with boceprevir/
peginterferon/ribavirin (as defined by the European Medicines Agency), treatment
with peginterferon/ribavirin, and no treatment. The second part of the model sim-
ulated the natural history of HCV. All hepatitis C-related state transition probabil-
ities were obtained from previously published studies. Lifetime cumulative inci-
dence of decompensated cirrhosis, hepatocellular carcinoma, liver-transplant and
liver-related death was estimated. The model was validated with previously pub-
lished studies and probabilistic sensitivity analysis was performed. RESULTS: Per
10,000 treatment-experienced patients, treatment with boceprevir/peginterferon/
ribavirin vs. treatment with peginterferon/ribavirin vs. no treatment, respectively,
were associated with substantial reductions in projected cases of decompensated
cirrhosis (1082 vs. 2286 vs. 2845), hepatocellular carcinoma (719 vs. 1440 vs. 1787),
liver-transplant (154 vs. 321 vs. 398), and liver-related death (1144 vs. 2360 vs. 2920).
Likewise, substantially fewer cases of decompensated cirrhosis (1024 vs. 1835 vs.
2873), hepatocellular carcinoma (656 vs. 1161 vs. 1806), liver-transplant (146 vs. 257
vs. 402), and liver-related death (1073 vs. 1892 vs. 2954) were projected per 10,000
treatment-naïve patients. CONCLUSIONS: Boceprevir-based regimens are pro-
jected to substantially reduce the incidence of liver-related complications and
mortality in previously untreated and treatment-experienced patients chronically
infected with hepatitis C virus genotype 1 in Germany.
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OBJECTIVES: To consider reliable sources of data to assess epidemiology of hospi-
tal-acquired infections (HAI) in intensive care units (ICU).METHODS: In order to get
epidemiological data, a literature review (2002–2009) focused on bloodstream in-
fection (BSI), catheter related BSI (CR-BSI) and ventilator-associated pneumonia
(VAP) in hospital ICU in the US was performed using EMBASE database, completed
with data from Centers for Disease Control & Prevention (CDC). US hospital data-
bases (2007) were also considered to put findings in perspective: Premier Perspec-
tiveTM Hospital Database (PPHD) and State Inpatient Database (SID: part of health
care cost and utilization project (HCUP)) providing ICU data for this study.
RESULTS: The rate of ICU hospitalized patients in the US databases (9.4%) was
within the results in literature (8%-15%). The proportion of ICU patients with de-
vices was higher in literature than in SID and PPHD databases with for central line
catheters: 48%, 19%, 26.2% and for mechanical ventilation: 33%, 21.9% and 15%
respectively. CR-BSI were reported in 4.8% of ICU patients with central venous
catheter, in literature (1.4 - 5.5 /1,000 central line days), 9.4% in SID (5.7/1,000 cath-
eter/central line days) and 33.8% in PPDH*. Rate of VAP in ICU was estimated at
2.1-10.7/1,000 ventilator days in literature and 12.2/1,000 ventilator days in SID.
Proportion of VAP amongst ICU mechanically ventilated patients was similar
within the databases (12%). BSI attributable mortality was comparable in the liter-
ature (12-25%) and hospital database (24.7% in PPHD). Attributable mortality for
VAP was not found in the literature. This latter was estimated from the hospital
database (19.6% in PPHD). CONCLUSIONS: Different sources are available to esti-
mate the prevalence of HAI in ICU. Results should be interpreted with caution due
to methodology limitations (e.g. HAI case definitions). Nevertheless, real-life data-
bases appear appropriate to estimate attributable mortality of HAI in ICU. * central
venous/line catheter.
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OBJECTIVES: To evaluate treatment outcomes in tuberculosis patients with and
without diabetes mellitus. METHODS: This was a retrospective cohort study con-
ducted at respiratory clinic of Hospital Pulau Pinang (HPP), Malaysia. All Tubercu-
losis (TB) patients who were presented to the clinic from January 2006 to December
2007 were included in the study. A purpose developed valid data collection form
was used for collecting demographic and clinical data. Treatment outcomes ini-
tially recorded as cured, treatment completed, defaulted, transferred out, expired
and treatment continued were then classified into two categories; successful and
unsuccessful treatment. Cured and treatment completed patients were placed in
treatment successful category while the rest were placed in the category of unsuc-
cessful treatment. Data was analyzed by using SPSS 16®. RESULTS: Final analysis
included 1266 patients.Three hundred and thirty eight patients (26.7%) had DM
along with TB. In multivariate analysis TB-DM was more likely to be present in
Chinese (OR 1.470, p-value 0.003), married patients (OR 1.408, p-value 0.011)
and patients having age 46-60 years (OR 2.002, p-value0.001), and 60 years (OR
 1.594, p-value  0.010). Nine hundred and eighty five (78.8%) patients were suc-
cessfully treated. Successful Treatment was observed in patients having age of
46-60 years (OR 1.567, p-value 0.001), whereas male gender (OR 0.721, p-value
 0.049) and patients with relapse TB (OR  0.494, p-value  0.002) were less likely
to have successful treatment. CONCLUSIONS: In the present study Chinese ethnic-
ity, age ( 46 years) and being married were the predictors of prevalence of TB-DM.
Majority patients were successfully treated. Male gender and patients with relapse
TB were the predictors of treatment failure. No statistically significant difference in
treatment outcomes was observed between TB patients with and without diabetes
mellitus.
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OBJECTIVES:Despite the availability of highly efficacious pharmacotherapy, tuber-
culosis (TB) still remains as a major public health problem globally. The aim of the
present study was to evaluate TB treatment outcomes in four high burden TB states
of Malaysia. METHODS: This was a retrospective prospective study conducted at
TB clinics of Penang, Sabah, Sarawak and Selangor. All TB patients who were pre-
sented to the clinics from January 2006 to December 2008 were included in the
study. A purpose developed valid data collection form was used for collecting de-
mographic and clinical data. World Health Organization (WHO) defined criteria
was used for defining treatment outcomes. Data was analyzed by using SPSS 16®.
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RESULTS: Final analysis included 9337 patients. Mean age of patients was 41.75 
10.11 years. Sixty nine percent patients were males. Treatment success rate was
77.5% (n  7240). Among 7240 successfully treated patients, 5319 patients cured
while 1921 completed their treatment. Among 22.5% (n2097) unsuccessfully
treated patients, 503 died, 502 defaulted, 369 transferred out and 723 were on
treatment continued. In multivariate analysis new TB infection (OR1.315,
p-value0.001) was the only factor associated with successful treatment outcome.
Whereas extra pulmonary TB (OR0.541, p-value0.001), pulmonary  extra pul-
monary TB (O 0.523, p-value0.001), urban area (OR0.889, p-value0.030),
smoking (OR0.890, p-value0.030), alcohol consumption (OR0.807,
p-value0.011) intravenous drug use (OR0.676, p-value0.001) and employment
(OR0.507, p-value0.001) had statistically significant negative association with
successful treatment outcome. CONCLUSIONS: Although more than three fourth
(77.5%) patients were treated successfully but the treatment success rate is still
behind the WHO target of 85%. In future more attention should be paid to patients
with extra pulmonary TB, belonging to urban area, smokers, alcohol consumers,
intravenous drug users and employees.
PIN18
RATES OF INFLUENZA COMPLICATIONS BY HIGH RISK GROUP
Mauskopf J1, Lee S2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Johnson & Johnson Pharmaceutical
Services, LLC, Horsham, PA, USA
OBJECTIVES: An unmet need remains for new effective treatments and/or man-
agement strategies for influenza in high-risk groups. Complications and mortality
rates might differ among high risk groups, such as those who are aged 65 years and
older compared with those with different chronic underlying medical conditions.
METHODS: A literature review was performed using electronic database keyword
searches, specific inclusion and exclusion criteria, quality rating of the reviewed
full-text articles, and abstraction of data to evaluate the published evidence on the
incidence, complication rates, and health service use associated with clinical in-
fluenza in different high-risk groups. RESULTS: Key findings for incidence rates of
clinical influenza were that these rates are similar among people with chronic
cardiovascular or respiratory comorbidity but may be higher in those with alloge-
neic stem cell transplants compared to those with autologous transplants. Rates of
hospitalization and/or pneumonia or lower respiratory tract infection for those
with chronic conditions or those who are immunocompromised (2.9% to 80%) are
significantly higher than those in people over age 65 but without additional high-
risk factors (0%). A person who is hospitalized and has a laboratory-confirmed
influenza diagnosis has a probability of intensive care unit admission of between
11.8% and 28.6% and of death of between 2.9% and 14.3%. Most of the studies of
hospitalized patients did not present outcomes data separately by high-risk group.
In addition, the rates and outcomes of influenza complications in all high-risk
groups are variable from year to year depending on the circulating influenza
viruses. CONCLUSIONS: These findings indicate that the burden of influenza may
vary by high-risk group although there are only limited data available to quantify
these differences. This information could be used to evaluate new therapies, in-
cluding better influenza vaccines, chemoprophylaxis, and/or treatment strategies
for different high-risk groups.
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OBJECTIVES: In the UK, PPV23 has been recommended in the elderly (aged 65 and
over) and at-risk adults. In 2007, PCV was introduced in children, leading to a
decrease in invasive pneumococcal disease (IPD) incidence associated with the PCV
serotypes not only in vaccinated children but also in unvaccinated adults. The use
of PCV13 in adults is currently under consideration pending data on efficacy in this
population. This study aimed to assess the BI of PPV23 vs. NoVac or PCV13 in the
UK, accounting for recent epidemiological changes. METHODS: The model was
adapted from a previous population-based Markov model, consisting of five health
states: no PD, IPD, NBPP (non-bacteraemic pneumococcal pneumonia), post-men-
ingitis sequelae and death. Epidemiology and costs were estimated from UK
sources. The analysis tracked cohorts of vaccinated and unvaccinated population
between 2012 and 2016. Four scenarios were tested and equal market shares were
assumed between PCV13 and PPV23. RESULTS: Over the study period, PPV23 vac-
cination led to a reduction in the number of IPD cases, ranging from 1,773 to 1,957
(vs. NoVac) or from -154 to 617 (vs. PCV13). The reduction in the number of NBPP
cases ranged from -2 to 23,969 (vs. NoVac) or from -11,984 to 0 (vs. PCV13). When
compared to NoVac, PPV23 vaccination was associated with a total cost of £63
million, whereas introducing PCV13 required an additional funds of £54 million.
The net budget impact ranged between £36 million and £59 million (vs. NoVac) or
between -£56 million and -£47 million (vs. PCV13). CONCLUSIONS: The model sug-
gests that vaccinating with PPV23 significantly reduces the burden of pneumococ-
cal disease despite the epidemiological changes. Introducing PCV13 is likely to
impose a significant impact on the health care budget and assumptions around the
efficacy of PCV13 are a substantial source of uncertainty in its public health bene-
fits.
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OBJECTIVES: The gradual increase of persons living with HIV, mainly due to the
reduced mortality achieved with effective antiretroviral therapies, calls for in-
creased rationality and awareness in health resources consumption also during
the early illness phases. Aim of this work is the estimation of the budget impact
related to the variation in backbone prescribing trends in naïve patients.
METHODS:Target population is the number of patients starting antiretroviral ther-
apy each year, according to the Italian HIV surveillance registry, excluding patients
receiving non-authorized or non-recommended regimens. We modeled 3-year
mortality and durability rates on a dynamic cohort, basing on international litera-
ture. Current Italian market shares of triple regimens containing first-choice back-
bones (TDF/FTC, ABC/3TC, TDF3TC, AZT/3TC) are compared to an hypothetical
scenario in which all patients eligible to ABC/3TC treatment (HLA-B*5701 negative
patients with 100,000 HIVRNA copies/mL) start a regimen containing this back-
bone as first line strategy. Annual cost for each regimen comprises drugs acquisi-
tion under hospital pricing rules, and monitoring exams and preventive tests, val-
ued basing on regional reimbursement tariffs. RESULTS: According to current
prescribing trends, in the next three years about 13,000 patients starting HIV ther-
apy will receive TDF/FTC (83% of the target population), and minor portions other
regimens (9% ABC/3TC, 8% AZT/3TC). Patients that would be eligible to ABC/3TC are
about six thousand more than those presently treated with this backbone, leading
to a saving of 3.1 million Euro over the three-year period. Sensitivity analyses on
different hypotheses of “third” drug market shares indicate savings ranging from
720 thousand to 3.9 million Euro. Most of this amount is due to reduced acquisition
costs and, secondarily, to lower monitoring needs. CONCLUSIONS: Where patient
features don’t force the choice of the backbone, ABC/3TC prescription may induce
substantial savings, allowing the release of resources needed to manage more
complicated/advanced cases.
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OBJECTIVES: To determine the economic impact of three different hospital-ac-
quired infections (HAI) in mechanically ventilated (MV) patients in intensive care
unit (ICU) and assess the attributable costs, hospital length of stay (LOS) and inpa-
tient mortality in a U.S. hospital database. METHODS: A U.S. retrospective cohort
study was undertaken using hospital database from the Premier Perspective of
adults (18 years old) with a stay  48h in 2007. Three HAIs were followed: blood-
stream infection (BSI), surgical site infection (SSI), and hospital-acquired pneumo-
nia (HAP) including ventilator-associated pneumonia (VAP). From a previous anal-
ysis, MV device was identified as an impactful risk factor in ICU showing higher
prevalence for HAP/VAP and BSI. Case subjects were defined as patients with HAI
event among the MV population. Economic criteria were defined as hospital LOS,
inpatient mortality and inpatient costs. RESULTS: Out of 463,491 patients meeting
the entry criteria, 101,540 (21.9%) received a MV setting. Focusing on this MV pop-
ulation, 51,683 (50.9%) patients developed HAI: HAP/VAP: 33.2%, BSI: 29.4%, and SSI:
2.3%. Compared with control, patients with HAI were more elderly (54% vs. 49%),
were more likely to be admitted via emergency room (86% vs. 78%), presented with
more severe illnesses, higher risk of mortality, and with central catheter place-
ments (67% vs. 39%). The inpatient mortality rate and mean LOS were higher in
patients with HAI (32% vs. 18% and 21.222.3 vs. 11.811.4 days, respectively).
Mean total costs were higher in HAI patients (56,751US$) compared to non-HAI
patients (34,032US$). In MV population, HAI patients had higher consumptions of
inpatient resources and inpatient mortality: extended LOS equal to 9.4 days, in-
creased total inpatient costs equal to 22,719US$ and extended mortality of 14%.
CONCLUSIONS: These data illustrate the significant economic burden and mortal-
ity of HAI in a category of at-risk population on MV and request the needs for
intervention.
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Pneumococcal diseases (PD), such as bacteremia, meningitis and pneumonia, are
associated with substantial burden in adults (50 years). Moreover, adults with
underlying chronic conditions (i.e., vascular, metabolic, or respiratory diseases)
have shown to have 3–6 times higher risk of PD compared with their healthy
controls. These people at higher risk will likely benefit most of PCV13 vaccination in
the new adult indication. OBJECTIVES: To estimate the expected 5-year economic
impact of targeted PCV13 vaccination compared to no vaccination in Finnish adults
(50 years) at higher risk for PD. METHODS: A budget impact model applying a
modified Markov-type structure was developed to predict the impact of PCV13
vaccination in terms of costs and PD events avoided. The model was built as a
dynamic open-cohort model to allow the annual evolution of the size of prevalent
target population with considered PCV13 indications. The results of model were
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